Sponsors & Exhibitors
Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT:SAN) and in New York (NYSE: SNY).
Route de Perreux 1 - 2017
+41 32 729 85 00
Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. We seek to deliver truly innovative and life-changing drugs for our patients through the discovery, development, and commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. Celgene employs more than 7,000 employees worldwide.
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/emea. Follow us at www.twitter.com/janssenEMEA.
Neopharm Israel is dedicated to the marketing and sales of premium ethical prescription products – pharmaceuticals, orphan drugs and biologic drugs.
Neopharm Israel is the exclusive representative and partner of leading multinational bio-pharma and consumer healthcare brands including Alexion, Celgene, Fresenius and many more.
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.
8 Calthorpe road,
Tel: + 44 (0) 121 456 9500
Fax: +44 (0) 121 456 9749
Web site: www.bindingsite.com
Binding Site is committed to improving patient lives worldwide through education, collaboration and innovation. Discover how your multiple myeloma patients could benefit from Binding Site’s Freelite® and Hevylite® assays.
Freelite is the ONLY serum free light chain test recommended by international and national guidelines, and is supported by more than 15 years of clinical evidence. The complementary Hevylite test adds additional information for “difficult-to-monitor” myeloma patients.
Using Freelite and Hevylite together is the best multiple myeloma monitoring strategy.
Visit us on stand 2.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development and subsequent commercialization of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases.
Our scientific expertise is focused on understanding the regulation of intracellular communication between the nucleus and the cytoplasm. We have discovered and are developing novel, small molecule Selective Inhibitor of Nuclear Export, or SINE™, compounds that inhibit the nuclear export protein XPO1. These SINE™ compounds represent a new class of drug candidates with a novel mechanism of action that have the potential to treat a variety of diseases in areas of unmet medical need. Our SINE™ compounds were the first oral XPO1 inhibitors in clinical development.
The Association for Training, Education and Research in Hematology, Immunology and Transplantation (ATERHIT) is a non-for profit scientific organization based in Paris (France).
ATERHIT aims to promote clinical, translational and basis research in the fields of hematology, immunology and stem cell transplantation through direct or indirect support to research projects. It also organizes a broad portfolio of eductional activities with the goal to disseminate knowledge in its fields of interest and enhance collaborations among all stakeholders. ATERHIT provides support for students, fellows, junior doctors, nurses, and other healthcare professionals who wish to train or gain more experience in this field. The organization can distribute prizes to acknowledge some major achievements in these fields."